Readers of this blog know that I frequently point readers to the work of John Ioannidis, MD, DSc, chief of the Stanford Prevention Research Center. Here are several updated items in the news:
A Stanford Med School blog published a piece, “Tropical disease treatments need more randomized, controlled trials,” citing an analysis published in the British Medical Journal of medical interventions for 16 tropical diseases. The authors found that, for most, there is little reliable evidence for the efficacy of one intervention versus another. According to Ioannidis:
“These 16 diseases have an enormous impact on health on a global level. More than a billion people are affected by them, and every year the disease burden from these diseases amounts to 57 million disability-adjusted life years. Although close to 1000 trials have been performed on different treatments for these diseases, they are are done one at a time and there is no coordination of the total research agenda that emerges.”
And Reuters Health reported, “Medicine rarely a slam dunk, despite splashy studies,” about a JAMA article Ioannidis co-authored and an accompanying editorial by Dr. Andy Oxman of the Norwegian Knowledge Centre for the Health Services.
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Comments are closed.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like